Thyroid Stimulating Immunoglobulin (TSI)
Autoimmune thyroid diseases are characterized by the presence of autoantibodies against various components of the thyroid glands including thyroperoxidase (TPO), thyroglobulin (Tg), TSH receptors (TSHR), and thyroid colloidal antigens. Polyclonal autoantibodies against TSHR that stimulate the receptor are associated with Graves’ Disease, neonatal thyrotoxicosis (maternally derived antibodies) and some cases of Hashimoto’s thyroiditis. Measurement of thyroid-stimulating immunoglobulins (TSI) are particularly helpful in the diagnosis and monitoring of patients with Graves’ disease and TSIs are present in 80% to 90% of these patients. Grave’s disease affects approximately 0.4% of the US population. Women are more frequently affected by Graves’ disease with ratio of women to men of 5:1. TSI should be measured in pregnant women with Graves’ disease to assess the risk of neonatal thyrotoxicosis from maternal IgG crossing the placenta. Higher values of TSI increase] the risk of neonatal thyrotoxicosis.
In Hashimoto’s thyroiditis (chronic autoimmune thyroiditis) patients typically demonstrate hypothyroidism due to the gradual autoimmune destruction of the gland by anti-Tg and Anti-TPO antibodies. In Hashimoto’s patients with anti-TSHR antibodies they typically bind to the TSH receptor and block its function. The small number of Hashimoto’s patients with stimulating antibodies may present initially with hyperthyroidism (‘Hashitoxicosis’) but in late stage patients it is thought that prior destruction of thyroid gland tissue blunts the TSI stimulatory effect.
Autoantibodies like thyroperoxidase antibody (TPOA), thyroglobulin antibody (TGA) are also found in both Graves’s disease and Hashimoto thyroiditis and therefore, are not useful in differentiating these disorders.
- As an aid in diagnosis and management of Graves’ disease
- Useful in differential diagnosis of autoimmune thyrotoxicosis
- Useful in the assessment of neonatal thyrotoxicosis in pregnant women with history of Graves’s disease
Increased in:
- Graves’ disease
- Hashitoxicosis
- Neonatal thyrotoxicosis
< 1.3 TSI index
Serum (SST).
Stability
- Ambient: 1-3 days
- Refrigerated: 5-7 days
- Frozen: 30 days
- Endocr J. 1998;45(6):701-8. [PMID: 10395224]
- N Engl J Med. 1983;309(17):1028-34. [PMID: 6137770]
- N Engl J Med. 1982;307(24):1499-507. [PMID: 6292715]
- J Endocrinol Invest. 1997;20(8):452-61. [PMID: 9364248]
- Ann Lab Med. 2019;39(1):3-14. [PMID: 30215224]
- Pediatrics. 2016;137(4):e20151878. [PMID: 26980880]